Cardiomyopathy News and Research

RSS

Cardiomyopathy is a group of diseases with primary, usually diffuse, involvement of the myocardium. The myocardial disease is not secondary to ischaemic, valvular, congenital or pericardial disease.

New analysis of heart structure, function for prevention of cardiac emergencies in basketball players

An analysis of the cardiac structure and function of more than 500 National Basketball Association (NBA) players provides information that can be incorporated into clinical assessments for the prevention of cardiac emergencies in basketball players and the athletic community at large, according to a study published online by JAMA Cardiology.

25 Feb 2016

SOM0226 (tolcapone) drug could significantly improve pharmacological treatment of ATTR

Researchers at the Institute of Biotechnology and Biomedicine, Universitat Autònoma de Barcelona (IBB-UAB), in collaboration with the biopharmaceutical company SOM Biotech, located in the Barcelona Science Park (PCB), have published, in Nature Communications, the results of a drug repositioning study in which they describe a powerful drug, SOM0226 (tolcapone) that could significantly improve the pharmacological treatment of familial transthyretin amyloidosis (ATTR).

24 Feb 2016

Cardiac MRI imaging assesses myocardial damage

In a world-first, researchers from Charité-Universitätsmedizin Berlin and the Max Delbrück Center for Molecular Medicine (MDC) have performed cardiac MRI imaging using a 7T MRI scanner in a patient-based study.

11 Feb 2016

Positive data on ability of MyoKardia’s MYK-461 to prevent development of HCM published in Science

MyoKardia, Inc., a clinical stage biopharmaceutical company pioneering a precision medicine approach for the treatment of heritable cardiovascular diseases, today announced the publication of an article in the leading medical journal Science.

8 Feb 2016

Scientists develop potential treatment to prevent hypertrophic cardiomyopathy

More than 15 years ago, David Warshaw, Ph.D., and coworkers discovered the precise malfunction of a specific protein in the heart that leads to hypertrophic cardiomyopathy, a common culprit in cases of sudden death in young athletes.

7 Feb 2016

Cardiovascular considerations crucial for CML TKI patients

A review of BCR–ABL1 tyrosine kinase inhibitors highlights the need to consider cardiovascular adverse event risk profiles when prescribing for patients with chronic myeloid leukaemia.

22 Jan 2016

New method helps generate cardiac cells for heart disease studies, drug discovery

For a team of Vanderbilt investigators trying to generate heart muscle cells from stem cells, a piece of broken equipment turned out to be a good thing.

18 Jan 2016

Novel therapy may help in diagnosing, treating heart disease in humans

A novel therapy tested by University of Guelph scientists for treating a fatal heart disorder in dogs might ultimately help in diagnosing and treating heart disease in humans.

12 Jan 2016

American College of Cardiology to honor LA BioMed researcher with Distinguished Teacher Award

John Michael Criley, MD, a Los Angeles Biomedical Research Institute researcher, will receive the 2016 Distinguished Teacher Award from the American College of Cardiology on April 4 at the organization's 65th Annual Scientific Session in Chicago, IL.

11 Jan 2016

Penn study provides new insight into cause of peripartum cardiomyopathy in pregnant women

Each year approximately 1 in 1,000 pregnant women will experience peripartum cardiomyopathy, an uncommon form of often severe heart failure that occurs in the final month of pregnancy or up to five months following delivery. But the cause of peripartum cardiomyopathy has been largely unknown - until now.

7 Jan 2016

Scientists find genetic link to unexplained heart failure affecting pregnant women

Scientists have found that women who suffer unexplained heart failure towards the end of pregnancy or shortly after giving birth share certain genetic changes.

7 Jan 2016

UT Southwestern scientists use new gene-editing technique to prevent progression of DMD in young mice

Using a new gene-editing technique, a team of scientists from UT Southwestern Medical Center stopped progression of Duchenne muscular dystrophy (DMD) in young mice.

4 Jan 2016

Researchers identify underlying molecular mechanism of cardiac hypertrophy

Specific genes are responsible for determining cell growth and differentiation during the early stages of cardiac development. Reactivation of these genes later in life can lead to an abnormal thickening of the heart muscle. Researchers from Charité -- Universitätsmedizin Berlin lead by Professor Silke Rickert-Sperling have been able to identify the underlying molecular mechanism.

23 Dec 2015

TGen, Barrow researchers identify genetic risk factors linked to stress-induced cardiomyopathy

Researchers at the Translational Genomics Research Institute and Barrow Neurological Institute have for the first time identified genetic risk factors that are linked to stress-induced cardiomyopathy (SIC), a rare type of heart disease.

1 Dec 2015

New doctoral thesis reveals potential treatment for stress-induced cardiomyopathy

Stress induced cardiomyopathy after cerebral hemorrhage has been shown to increase the risk of further brain damage. These patients can now be identified by a simple blood test, and a possible treatment for stress induced cardiomyopathy has been discovered - a different kind of anesthesia than that currently being used. A new doctoral thesis at Sahlgrenska Academy has explored these issues.

26 Nov 2015

Mylan releases Clozapine Orally Disintegrating Tablets in U.S.

Mylan N.V. today announced the U.S. launch of Clozapine Orally Disintegrating Tablets, 25 mg and 100 mg, the generic version of Jazz Pharmaceutical's FazaClo.

24 Nov 2015

AstraZeneca announces FDA approval of TAGRISSO (AZD9291) for treatment of lung cancer patients

AstraZeneca today announced that the US Food and Drug Administration has approved TAGRISSO (AZD9291) 80mg once-daily tablets for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an FDA-approved test, who have progressed on or after EGFR tyrosine kinase inhibitor (TKI) therapy.

17 Nov 2015

Cotellic (cobimetinib) approved to be used in combination with vemurafenib for melanoma treatment

The U.S. Food and Drug Administration today approved Cotellic (cobimetinib) to be used in combination with vemurafenib to treat advanced melanoma that has spread to other parts of the body or can't be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation).

10 Nov 2015

New funding for Centenary's life saving research

The Centenary Institute has welcomed the Federal Government’s announcement of funding for 9 new and innovative medical research projects via the latest round of NHMRC grant rounds funding, officially confirmed today.

9 Nov 2015

Alnylam presents positive ongoing phase 2 open-label extension data for Patisiran and Revusiran

Alnylam Pharmaceuticals, Inc. has announced new results from its ongoing Phase 2 open-label extension (OLE) studies with patisiran and revusiran, investigational RNAi therapeutics targeting transthyretin (TTR) for the treatment of TTR-mediated amyloidosis (ATTR amyloidosis).

3 Nov 2015